Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical company (Nasdaq: EIKN) founded in 2019 and headquartered in Millbrae, California, with additional offices in New York and Jersey City. Eikon built a proprietary drug-discovery platform around single-molecule live-cell imaging, applying super-resolution fluorescence microscopy and high-throughput single-molecule tracking to observe how proteins and drug targets move and interact inside living cells in real time. The technology descends from co-founder Eric Betzig's Nobel Prize-winning work in super-resolution microscopy, and the company is led by former Merck R&D chief Roger Perlmutter. Eikon uses these measurements to discover and develop novel therapeutics across oncology and other disease areas. This profile was surfaced as a portfolio company of Lux Capital and enriched by the API Evangelist pipeline; Eikon publishes a corporate and investor web presence but no public developer API, SDK, or machine-readable API surface at this time.

Eikon Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech, Biopharmaceutical, Drug Discovery, and Live-Cell Imaging.

Eikon Therapeutics’ developer surface includes product news and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechBiopharmaceuticalDrug DiscoveryLive-Cell ImagingSuper-Resolution MicroscopyOncologyLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 10.8/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/eikon-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

About

News

Careers

Investors

LinkedIn

Source (apis.yml)

aid: eikon-therapeutics
name: Eikon Therapeutics
description: 'Eikon Therapeutics is a biopharmaceutical company (Nasdaq: EIKN) founded in 2019 and headquartered in Millbrae,
  California, with additional offices in New York and Jersey City. Eikon built a proprietary drug-discovery platform around
  single-molecule live-cell imaging, applying super-resolution fluorescence microscopy and high-throughput single-molecule
  tracking to observe how proteins and drug targets move and interact inside living cells in real time. The technology descends
  from co-founder Eric Betzig''s Nobel Prize-winning work in super-resolution microscopy, and the company is led by former
  Merck R&D chief Roger Perlmutter. Eikon uses these measurements to discover and develop novel therapeutics across oncology
  and other disease areas. This profile was surfaced as a portfolio company of Lux Capital and enriched by the API Evangelist
  pipeline; Eikon publishes a corporate and investor web presence but no public developer API, SDK, or machine-readable API
  surface at this time.'
url: https://raw.githubusercontent.com/api-evangelist/eikon-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lux-capital
x-tier: stub
x-tier-reason: portfolio-lead
x-ticker: EIKN
x-hq: Millbrae, California, United States
x-founded: '2019'
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.eikontx.com/wp-content/uploads/2023/12/logo-eikon.png
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotech
- Biopharmaceutical
- Drug Discovery
- Live-Cell Imaging
- Super-Resolution Microscopy
- Oncology
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/eikon-therapeutics-domain-security.yml
- type: Website
  url: https://www.eikontx.com
- type: About
  url: https://www.eikontx.com/about-us/
- type: News
  url: https://www.eikontx.com/news/
- type: Careers
  url: https://www.eikontx.com/careers/
- type: Contact
  url: https://www.eikontx.com/contact/
- type: Investors
  url: https://investors.eikontx.com/
- type: PrivacyPolicy
  url: https://www.eikontx.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/eikon-therapeutics-inc/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence